Oucome of resection of invasive fungal disease of the lung in pediatric hemato-oncological patients
Recruiting
- Conditions
- Proven/probable invasive fungal diseases (IFD) of the lung according to definition of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORTC/MSGERC).
- Registration Number
- DRKS00024719
- Lead Sponsor
- niversitätsklinikum Freiburg, Klinik für Thoraxchirurgie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
1. Hemato-oncological Patients = 18 years of age at the time of the first diagnosis of blood malignancy or at the time of undergoing allogeneic hematopoietic stem cell transplantation (HSCT)
2. Treated at the Dept. for Thoracic Surgery or at the Dept. of Pediatric Hematology and Oncology from 01/2003-12/2020.
3. Proven/probable invasive fungal diseases (IFD) of the lung according to definition of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
(EORTC/MSGERC).
Exclusion Criteria
none
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The complete remission of IFD after combined lung resection and antifungal therapy compared with antifungal therapy alone.
- Secondary Outcome Measures
Name Time Method • 30-day postoperative mortality and morbidity after surgery.<br>• Duration of antifungal therapy<br>• Overall survival and recurrence rates of IFD Duration of antifungal therapy